

Diana S Osorio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7699456/publications.pdf>

Version: 2024-02-01

32
papers

307
citations

1163117

8
h-index

940533

16
g-index

34
all docs

34
docs citations

34
times ranked

665
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29365.	1.5	3
2	Epidemiological characteristics and survival outcomes of children with medulloblastoma treated at the National Cancer Institute (INCA) in Rio de Janeiro, Brazil. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29274.	1.5	3
3	Factors influencing outcomes of older children with medulloblastoma over 15 years in Peru, a resource-limited setting. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29770.	1.5	3
4	LINC-23. Factors influencing outcomes of older children with Medulloblastoma over 15 years in Peru, a resource limited setting. <i>Neuro-Oncology</i> , 2022, 24, i167-i167.	1.2	0
5	Validated quantitative needs assessment differences in the management of children with central nervous system cancer between Brazil, an upper middle-income country, and the United States of America, a high income country. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28958.	1.5	2
6	Evaluation of the Pediatric Neuro-Oncology Resources Available in Chile. <i>JCO Global Oncology</i> , 2021, 7, 425-434.	1.8	3
7	Follow-up evaluation of a web-based pediatric brain tumor board in Latin America. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29073.	1.5	7
8	Abstract CT018: Phase I immunovirotherapy trial of oncolytic HSV-1 G207 alone or combined with radiation in pediatric high-grade glioma. <i>Cancer Research</i> , 2021, 81, CT018-CT018.	0.9	2
9	Discovery of clinically relevant fusions in pediatric cancer. <i>BMC Genomics</i> , 2021, 22, 872.	2.8	13
10	Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas. <i>Acta Neuropathologica Communications</i> , 2021, 9, 192.	5.2	5
11	Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas. <i>Acta Neuropathologica Communications</i> , 2020, 8, 182.	5.2	11
12	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. <i>JCO Precision Oncology</i> , 2020, 4, 561-571.	3.0	62
13	RARE-37. NOONAN SYNDROME AND GLIONEURONAL TUMORS: A CENTRAL NERVOUS SYSTEM CANCER PREDISPOSITION ASSOCIATION?. <i>Neuro-Oncology</i> , 2020, 22, iii450-iii450.	1.2	0
14	LINC-18. FOLLOW-UP EVALUATION OF A WEB-BASED PEDIATRIC BRAIN TUMOR BOARD IN LATIN AMERICA. <i>Neuro-Oncology</i> , 2020, 22, iii381-iii382.	1.2	0
15	GCT-25. INNOVATIVE, INTENSIVE IRRADIATION-AVOIDING/MINIMIZING CHEMOTHERAPY FOR HIGH-RISK PRIMARY CENTRAL NERVOUS SYSTEM (CNS) MIXED MALIGNANT GERM CELL TUMORS (HR-MMGCT): A PILOT STUDY AND PROPOSED MULTI-NATIONAL PROSPECTIVE TRIAL. <i>Neuro-Oncology</i> , 2020, 22, iii333-iii333.	1.2	0
16	EPEN-17. FAVORABLE OUTCOME TO INTENSIVE CHEMOTHERAPY WITHOUT IRRADIATION IN INFANTILE METASTATIC EPENDYMOMA WITH A NOVEL MOLECULAR PROFILE: A CASE REPORT. <i>Neuro-Oncology</i> , 2020, 22, iii310-iii311.	1.2	0
17	LINC-11. NEUROPATHOLOGY REVIEW OF LATIN AMERICAN CHILDHOOD AND ADOLESCENT BRAIN TUMOR PATIENTS: A MULTI-NATIONAL, MULTI-DISCIPLINARY PEDIATRIC NEURO-ONCOLOGY TELECONFERENCE EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, iii380-iii380.	1.2	0
18	RARE-40. CASE REPORT: LONG-TERM SURVIVOR OF A RARE, PEDIATRIC PRIMARY HISTIOCYTIC SARCOMA (HS) OF THE CENTRAL NERVOUS SYSTEM (CNS) FOLLOWING COMPLETE RESECTION, CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT). <i>Neuro-Oncology</i> , 2020, 22, iii451-iii451.	1.2	0

#	ARTICLE	IF	CITATIONS
19	A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition. <i>Oncolmmunology</i> , 2019, 8, e1678921.	4.6	18
20	Descriptive epidemiology of germ cell tumors of the central nervous system diagnosed in the United States from 2006 to 2015. <i>Journal of Neuro-Oncology</i> , 2019, 143, 251-260.	2.9	52
21	The Latin American Brain Tumor Board teleconference: results of a web-based survey to evaluate participant experience utilizing this resource. <i>Child's Nervous System</i> , 2019, 35, 257-265.	1.1	13
22	Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26776.	1.5	7
23	DEV-14. IMPACT OF A LATIN AMERICA-WIDE TELECONFERENCED BRAIN TUMOR BOARD. <i>Neuro-Oncology</i> , 2018, 20, i47-i48.	1.2	4
24	MBCL-33. HEPATOTOXICITY DURING INDUCTION CHEMOTHERAPY, WITH OR WITHOUT HIGH-DOSE METHOTREXATE (HD-MTX), ON THE HEAD START II TRIAL FOR PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. <i>Neuro-Oncology</i> , 2018, 20, i124-i124.	1.2	0
25	Pre-irradiation intensive induction and marrow-ablative consolidation chemotherapy in young children with newly diagnosed high-grade brainstem gliomas: report of the "head-start" and II clinical trials. <i>Journal of Neuro-Oncology</i> , 2018, 140, 717-725.	2.9	5
26	DEV-07. THE LATIN-AMERICAN BRAIN TUMOR BOARD (LATB) TELECONFERENCE: RESULTS OF A WEB-BASED SURVEY TO EVALUATE PARTICIPANT EXPERIENCE AND THE PROGRAM. <i>Neuro-Oncology</i> , 2018, 20, i46-i46.	1.2	1
27	EAPH-04. SAFETY AND TOLERABILITY OF CONCOMITANT MULTI-AGENT INTRA-VENTRICULAR CHEMOTHERAPY FOR THE TREATMENT OF RECURRENT CENTRAL NERVOUS SYSTEM (CNS) TUMORS. <i>Neuro-Oncology</i> , 2018, 20, i65-i66.	1.2	2
28	DEV-01. QUANTITATIVE NEEDS ASSESSMENT DIFFERENCES IN THE MANAGEMENT OF CHILDREN WITH CENTRAL NERVOUS SYSTEM (CNS) CANCER IN A MIDDLE-INCOME COUNTRY AND A HIGH-INCOME COUNTRY. <i>Neuro-Oncology</i> , 2018, 20, i45-i45.	1.2	0
29	Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2. <i>Journal of Neuro-Oncology</i> , 2018, 139, 749-755.	2.9	28
30	Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. <i>Acta Neuropathologica Communications</i> , 2017, 5, 78.	5.2	48
31	GC-05 MANAGEMENT OF PRIMARY INTRASELLAR/CAVERNOUS SINUS PURE EMBRYONAL CARCINOMA IN THE SETTING OF DOWN SYNDROME. <i>Neuro-Oncology</i> , 2016, 18, iii43.1-iii43.	1.2	0
32	SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature. <i>Child's Nervous System</i> , 2016, 32, 2439-2446.	1.1	15